Biden presses companies on infant formula, FDA eyes more imports
Reuters
Published May 18, 2022 06:40PM ET
Updated May 18, 2022 11:37PM ET
By Jeff Mason, Susan Heavey and Trevor Hunnicutt
WASHINGTON (Reuters) -U.S. President Joe Biden met on Thursday with executives from infant formula manufacturers and retailers including Target , Walmart (NYSE:WMT) and Nestle's Gerber, pressing them to do everything possible to get families access amid a nationwide shortage.
The White House also outlined measures the administration is taking to address the issue and said it was considering invoking the Defense Production Act.
The U.S. Food & Drug Administration (FDA) will announce new steps in the coming days regarding importing certain infant formula products from abroad, the White House said, and Biden has asked the Federal Trade Commission (FTC) to probe reports of predatory conduct such as price gouging.
Formula shortages because of a factory being taken offline have been compounded by supply chain snags and historic inflation, leaving about 40% of baby formula products out of stock nationwide, according to data firm Datasembly.
Families depend on formula. Less than half of babies born in the United States were exclusively breastfed through their first three months, the Centers for Disease Control and Prevention 2020 Breastfeeding Report Card showed.
During his meeting with the executives, Biden discussed efforts to increase production and urged companies to "do more to help families purchase infant formula," White House spokesperson Jen Psaki said.
"What we are seeing, which is an enormous problem, is hoarding," Psaki said. "That is also something we're focused on."
Biden later said on Twitter (NYSE:TWTR), "I'm announcing new actions and working with the private sector to get infant formula into stores as quickly as possible without compromising safety."
Tight supplies of formula dwindled further after Abbott Laboratories (NYSE:ABT) in February recalled Similac and other baby formula made at its Sturgis, Michigan, plant following consumer complaints of bacterial contamination. The FDA later cited five bacterial infections reported in babies given the company's formula, including two deaths.
Abbott, the biggest U.S. supplier of milk formula, said tests showed one bacteria strain found in the facility was not linked to any known infant illnesses, although it was updating its cleaning and related protocols.
Other major formula producers include Reckitt Benckiser and Nestle SA (SIX:NESN).
Several retailers, including Target Corp (NYSE:TGT), CVS Health Corp (NYSE:CVS) and Walgreens Boots Alliance (NASDAQ:WBA), have limited formula purchases until supplies improve to prevent hoarding. New York Attorney General Letitia James also has warned against price gouging.
Get The News You Want
U.S. House lawmakers plan a hearing on the matter on May 25. [L2N2X322B]
House Speaker Nancy Pelosi told reporters lawmakers want to ensure it does not happen again, "but right now the baby's crying, the baby's hungry and we need to address the situation right now."
Last month, House Appropriations Committee Chairwoman Rosa DeLauro sought a Department of Health and Human Services probe, citing a whistleblower report from October 2021.
On Thursday, House Republicans criticized the Biden administration, saying a plan should have been in place to address the shortages sooner.
Abbott said it could restart production at Sturgis within two weeks of FDA approval, adding it is prioritizing production at its Columbus, Ohio, facility and air-shipping formula from its Ireland plant.
The company announced the recall on Feb. 17.
On Feb. 28, the FDA warned of Cronobacter sakazakii and Salmonella Newport infections in babies fed with formula produced at the Michigan plant. The FDA finished inspecting that facility on March 18, and the company responded on April 8, Abbott said.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.